Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
36.07
+0.81 (2.30%)
At close: Aug 13, 2025, 4:00 PM
35.50
-0.57 (-1.58%)
After-hours: Aug 13, 2025, 7:55 PM EDT
Revolution Medicines Employees
Revolution Medicines had 534 employees as of December 31, 2024. The number of employees increased by 156 or 41.27% compared to the previous year.
Employees
534
Change (1Y)
156
Growth (1Y)
41.27%
Revenue / Employee
n/a
Profits / Employee
-$1,520,712
Market Cap
6.74B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RVMD News
- 6 days ago - Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 14 days ago - Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - GlobeNewsWire
- 20 days ago - Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewsWire
- 21 days ago - Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewsWire
- 5 weeks ago - Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates - GlobeNewsWire
- 6 weeks ago - Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors - GlobeNewsWire
- 6 weeks ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire